TY - JOUR
T1 - 2021 MiECTiS focused update on the 2016 position paper for the use of minimal invasive extracorporeal circulation in cardiac surgery
AU - Anastasiadis, Kyriakos
AU - Antonitsis, Polychronis
AU - Murkin, John
AU - Serrick, Cyril
AU - Gunaydin, Serdar
AU - el-Essawi, Aschraf
AU - Bennett, Mark
AU - Erdoes, Gabor
AU - Liebold, Andreas
AU - Punjabi, Prakash
AU - Theodoropoulos, Konstantinos C.
AU - Kiaii, Bob
AU - Wahba, Alexander
AU - de Somer, Filip
AU - Bauer, Adrian
AU - Kadner, Alexander
AU - van Boven, Wim
AU - Argiriadou, Helena
AU - Deliopoulos, Apostolos
AU - Baker, Robert Α
AU - Breitenbach, Ingo
AU - Ince, Can
AU - Starinieri, Pascal
AU - Jenni, Hansjoerg
AU - Popov, Vadim
AU - Moorjani, Narain
AU - Moscarelli, Marco
AU - di Eusanio, Marco
AU - Cale, Alex
AU - Shapira, Oz
AU - Baufreton, Christophe
AU - Condello, Ignazio
AU - Merkle, Frank
AU - Stehouwer, Marco
AU - Schmid, Christof
AU - Ranucci, Marco
AU - Angelini, Gianni
AU - Carrel, Thierry
N1 - Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Kyriakos Anastasiadis: Consulting agreement with Medtronic. Polychronis Antonitsis: Consulting agreement with Medtronic. Aschraf El-Essawi: Consulting agreement with Medtronic, speaker for Terumo and Edwards. Andreas Liebold: Consulting agreement with Edwards Lifesciences, educational grants from Getinge, LivaNova and Abbott. Bob Kiaii: Consulting agreement with Medtronic, Abbott, and Johnson and Johnson. Adrian Bauer: Advisory board of LivaNova, speaker for Köhler Chemie, advertisement and studies for Medtronic. Wim van Boven: Consulting agreement with Medtronic Helena Argiriadou: Consulting agreement with Medtronic. Hansjoerg Jenni: Consulting agreement with Medtronic. Marco Di Eusanio: Consulting agreement with Medtronic, Corcym and Edwards. Christophe Baufreton: Consulting agreement with Medtronic, Liva-Nova, Nordic Pharma and Cytosorbents. Ignazio Condello: Consulting agreement with Eurosets and Livanova. Marco Ranucci: Advisory Board Member for Medtronic and Livanova. All other authors declared no conflict of interest. Publisher Copyright: © The Author(s) 2022.
PY - 2022
Y1 - 2022
N2 - The landmark 2016 Minimal Invasive Extracorporeal Technologies International Society (MiECTiS) position paper promoted the creation of a common language between cardiac surgeons, anesthesiologists and perfusionists which led to the development of a stable framework that paved the way for the advancement of minimal invasive perfusion and related technologies. The current expert consensus document offers an update in areas for which new evidence has emerged. In the light of published literature, modular minimal invasive extracorporeal circulation (MiECC) has been established as a safe and effective perfusion technique that increases biocompatibility and ultimately ensures perfusion safety in all adult cardiac surgical procedures, including re-operations, aortic arch and emergency surgery. Moreover, it was recognized that incorporation of MiECC strategies advances minimal invasive cardiac surgery (MICS) by combining reduced surgical trauma with minimal physiologic derangements. Minimal Invasive Extracorporeal Technologies International Society considers MiECC as a physiologically-based multidisciplinary strategy for performing cardiac surgery that is associated with significant evidence-based clinical benefit that has accrued over the years. Widespread adoption of this technology is thus strongly advocated to obtain additional healthcare benefit while advancing patient care.
AB - The landmark 2016 Minimal Invasive Extracorporeal Technologies International Society (MiECTiS) position paper promoted the creation of a common language between cardiac surgeons, anesthesiologists and perfusionists which led to the development of a stable framework that paved the way for the advancement of minimal invasive perfusion and related technologies. The current expert consensus document offers an update in areas for which new evidence has emerged. In the light of published literature, modular minimal invasive extracorporeal circulation (MiECC) has been established as a safe and effective perfusion technique that increases biocompatibility and ultimately ensures perfusion safety in all adult cardiac surgical procedures, including re-operations, aortic arch and emergency surgery. Moreover, it was recognized that incorporation of MiECC strategies advances minimal invasive cardiac surgery (MICS) by combining reduced surgical trauma with minimal physiologic derangements. Minimal Invasive Extracorporeal Technologies International Society considers MiECC as a physiologically-based multidisciplinary strategy for performing cardiac surgery that is associated with significant evidence-based clinical benefit that has accrued over the years. Widespread adoption of this technology is thus strongly advocated to obtain additional healthcare benefit while advancing patient care.
KW - cardiopulmonary bypass
KW - extracorporeal circulation
KW - focused update
KW - minimal invasive extracorporeal circulation
KW - modular systems
UR - http://www.scopus.com/inward/record.url?scp=85135892153&partnerID=8YFLogxK
U2 - https://doi.org/10.1177/02676591221119002
DO - https://doi.org/10.1177/02676591221119002
M3 - Review article
C2 - 35961654
SN - 0267-6591
JO - Perfusion
JF - Perfusion
ER -